key: cord-0968945-yr0oxj1r authors: Walz, Lucas; Cohen, Avi J.; Rebaza, Andre P.; Vanchieri, James; Slade, Martin D.; Cruz, Charles S. Dela; Sharma, Lokesh title: JAK-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis date: 2020-08-26 journal: Res Sq DOI: 10.21203/rs.3.rs-64782/v1 sha: bb2e9b67ea5729b064ca5a0ff5cabc41a97de2df doc_id: 968945 cord_uid: yr0oxj1r Background The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 17 million. Novel therapies are urgently needed. Janus kinase-inhibitors and Type I interferons have emerged as potential antiviral candidates for COVID-19 patients for their proven efficacy against diseases with excessive cytokine release and due to direct antiviral ability against viruses including coronaviruses, respectively. We conducted a systemic review and meta-analysis to evaluate the effect of Janus kinase-inhibitors and Type I interferons and their ability to produce positive patient outcomes in COVID-19 patients. Methods A search of MEDLINE and MedRxiv was conducted by three investigators from inception until July 30 th 2020, including any study type that compared treatment outcomes of humans treated with JAK-inhibitor or Type I interferon against controls. Inclusion necessitated data with clearly indicated risk estimates or those that permitted their back-calculation. Outcomes were synthesized using RevMan. Results Of 733 searched studies, we included four randomized and eleven non-randomized trials. Five of the studies were unpublished. Those who received Janus kinase-inhibitor had significantly reduced odds of mortality (OR, 0.12; 95% CI, 0.03 – 0.39, p<0.001) and ICU admission (OR, 0.05; 95% CI, 0.01 – 0.26, p<0.001), and had significantly increased odds of hospital discharge (OR, 22.76; 95% CI, 10.68 – 48.54, p<0.00001), when compared to standard treatment group. Type I interferon recipients had significantly reduced odds of mortality (OR, 0.19; 95% CI, 0.04 – 0.85, p<0.05), and increased odds of discharge bordering significance (OR, 1.89; 95% CI, 1.00 – 3.59, p=0.05). Conclusions Janus kinase-inhibitor treatment is significantly associated with positive clinical outcomes in terms of mortality, ICU admission, and discharge. Type I interferon treatment is associated with positive clinical outcomes in regard to mortality and discharge. While these data show promise, additional well-conducted RCTs are needed to further elucidate the relationship between clinical outcomes and Janus kinase-inhibitors and Type I interferons in COVID-19 patients. The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as the 111 deadliest pandemic since influenza in 1918 and has proved to be the ultimate challenge for public health 112 organizations, health care providers, and governments at all levels. [1] Severe disease caused by SARS- CoV-2 (COVID-19) has strained intensive care unit (ICU) and personal protective equipment (PPE) 114 resources around the world, [2] leading to ICU mortality rates as high as 20% in some population Uncertainty and a lack of clinically proven prophylactic and therapeutic options have precipitated 151 the periodic update of treatment guidelines for patients infected with COVID-19. As such, systematic 152 reviews evaluating effects in larger patient populations are necessary to ascertain drug-related COVID-19 153 outcomes. In this meta-analysis, we evaluate Janus kinase-inhibitors and Type I interferons for their 154 efficacy and ability to produce positive outcomes in patients infected with SARS-CoV-2. Search Strategy and Study Quality Assessment 162 MEDLINE (via PubMed) and MedRxiv were searched since inception throughout July 30 th , 2020 163 by three investigators (LW, AC, JV). The following terms were searched in free-text fields for JAK-164 inhibitors. For MEDLINE: "COVID-19" AND "JAK inhibitor" OR "Ruxolitinib" OR "Tofacitinib" OR 165 "Fedratinib" OR "Baricitinib". For MedRxiv: "COVID-19 JAK inhibitor" OR "COVID-19 Ruxolitinib" OR 166 "COVID-19 Tofacitinib" OR "COVID-19 Fedratinib" OR "COVID-19 Baricitinib". The following terms were Randomized studies included in the final analyses were scored by one investigator (LW) to formally 174 assess for risk of bias utilizing the Risk of Bias (RoB) 2 tool (Supplementary Table 3 Intervals (CIs) are reported. Heterogeneity was assessed using tau-squared and chi-squared tests for 210 random effects and fixed effect models, respectively, as well as the I 2 statistic. For I 2 > 50%, the random 211 effects model was used. Otherwise, the fixed effects model was utilized. An alpha of 0.05 was adopted to 212 determine significance. 213 214 9 The initial database search returned 731 articles. Two additional articles were added by manually 217 searching retrieved reviews. After removing two duplicates, 698 articles were excluded following title and 225 Figure 1 presents the meta-analysis flow chart and Table 1 presents the designs and characteristics of 226 included studies. While some studies did not report which drugs were given to which patients as standard of care, 229 many others reported treating patients with glucocorticoids, hydroxychloroquine, chloroquine, arbidol, and 230 lopinavir/ritonavir. All studies were conducted within a hospital setting. A total of five studies investigated the effect of JAK inhibition in a controlled setting (Table 1) As SARS-CoV-2 continues to infect millions and kill thousands daily, there is an urgent need to 270 find novel therapies that can effectively limit COVID-19 severity. Type I interferon therapy as well JAK 271 inhibitors represent paradoxical approaches to treat COVID-19. While Type I interferon therapy aims to 272 limit the viral replication at the early time points to limit the subsequent disease, JAK-inhibitors aim to limit 273 the overt inflammation that may be detrimental to the host and cause systemic inflammatory response. Lucas Walz (LW); conception of investigation, planning of investigation, data retrieval, article screening, 380 data analysis, written reporting, data interpretation. Avi J. Cohen (AC); planning of investigation, data retrieval, article screening, data analysis, written 382 reporting, data interpretation. Andre P. Rebaza, MD (AR); written reporting, data interpretation. James Vanchieri (JV): data retrieval, article screening. JAK-inhibitor treatment group saw significantly reduced odds of mortality and ICU admission, as well as 551 significantly higher odds of discharge, when compared to standard treatment. There was no significant 552 difference between groups in regards to requiring mechanical ventilation, or the development of ARDS. The meta-analysis results are presented on forest plots, with a study's calculated OR plotted as a black 554 square whose size is proportional to the weight afforded to the study. Bidirectional bars stemming from 555 these black squares correspond to the risk estimate's 95% CI. Diamonds were used to represent the 556 summary OR; its center aligns with the OR and its width represents the summary 95% CI. Type I interferon group saw significantly reduced odds of mortality, as well as increased odds of 563 discharge that bordered significance, when compared to standard treatment. There was no significant 564 difference between groups in regards to requiring ICU admission, mechanical ventilation, or the 565 development of severe or critical disease. The meta-analysis results are presented on forest plots, with a 566 study's calculated OR plotted as a black square whose size is proportional to the weight afforded to the 567 study. Bidirectional bars stemming from these black squares correspond to the risk estimate's 95% CI. Diamonds were used to represent the summary OR; its center aligns with the OR and its width represents 569 the summary 95% CI. Studies presented in alphabetical order. Responding to Covid-19 -A Once-in-a-Century Pandemic? Fair Allocation of Scarce Medical Resources in the Time 406 of Covid-19 Clinical Characteristics of Covid-19 in New York City. N Engl 408 Remdesivir for the Treatment of Covid-19 -412 Preliminary Report Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to 12. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses Global virus outbreaks: Interferons as 1st responders Hepatitis C: therapeutic perspectives Acute Respiratory SyndromeA Preliminary Study Broad-spectrum antivirals for the emerging Middle East 437 respiratory syndrome coronavirus Young Men With Severe COVID-19 Impaired type I interferon activity and inflammatory 442 responses in severe COVID-19 patients Subcutaneous administration of interferon beta-1a for 444 COVID-19: A non-controlled prospective trial The PRISMA statement for reporting systematic reviews 447 and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration RoB 2: a revised tool for assessing risk of bias in 450 randomised trials Appraising the Quality of Medical Education Research Methods: The Medical 452 Education Research Study Quality Instrument and the Newcastle-Ottawa Scale-Education Prolonged SARS-CoV-2 Viral Shedding in Patients with 481 COVID-19 was Associated with Delayed Initiation of Arbidol Treatment: a retrospective cohort study Epidemiological and clinical features of 291 cases with 484 coronavirus disease 2019 in areas adjacent to Hubei, China: a double-center observational study Medical treatment of 55 patients with COVID-19 from seven cities in 487 northeast China who fully recovered: a single-center, retrospective, observational study Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients National Library of Medicine (US) National Library of Medicine (US) Persistent Viral Presence Determines the Clinical Course of the 499 Disease in COVID-19 Cytokine storm and leukocyte changes in mild versus severe 502 -2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and 503 therapy concepts A Comparison of Mortality-related Risk Factors of COVID-19 A Systematic Review and Meta-analysis Avenues of bias considered: Risk of bias arising from the randomization process, Risk of bias due to 588 deviations from the intended interventions (effect of assignment to intervention), Risk of bias due to 589 deviations from the intended interventions (effect of adhering to intervention), Risk of bias due to missing Study characteristics examined: (1) representativeness of exposed cohort, (2) selection of nonexposed 596 cohort, (3) exposure assessment, (4) outcome of interest not present at the start of the study, (5) 597 comparability of cohorts, (6) outcome assessment, (7)